Does KIN Health sell a GLP-1?
KIN advertises a single price including medication, provider care and messaging. Its GLP-1 menu groups several formulations without fully defining every drug-and-form option.
The verdict
The stated inclusion of ongoing provider care is useful, as is the explicit warning that KIN’s formulations have not been independently studied. Clarify the exact formulation and clinical review schedule before treating the broad product menu as a prescription plan.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Dose pricing
- Flat across doses
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
KIN Health, operated under Purpose Medical, Inc., offers telehealth weight and wellness treatment. Its homepage names semaglutide and tirzepatide within a wider GLP-1 category.
Who writes the prescription, and what do they see?
Licensed providers review the intake and make prescribing decisions. The page describes independent U.S. pharmacies but does not establish the individual clinician or dispensing pharmacy for a prospective patient.
The published sequence is quiz, clinician review, shipment if prescribed and ongoing support. Provider messaging and check-ins are advertised as included rather than an extra membership.
What happens when the dose goes up?
The site promises the same monthly price regardless of prescribed dose. It does not define a uniform check-in interval, so confirm when a clinician reviews tolerability and authorizes the next prescription.
What the price includes
Separate semaglutide and tirzepatide monthly figures are displayed, with no membership surcharge claimed. The exact formulation and supply attached to each must be confirmed before turning them into comparable injection or oral prices.
What it claims, and what it cites
KIN describes compounded treatment and groups injection, nasal and dissolvable-tablet formats in the GLP-1 menu. Compounded products are not FDA-approved; the site acknowledges that its formulations were not independently studied.
Where it holds up, and where it does not
- Strength: Ongoing care described as included
- Strength: Own-formulation evidence limit acknowledged
- Limitation: Format-to-product mapping incomplete
- Limitation: Visit frequency not specified
What the evidence says about this kind of treatment
The assessment above is about KIN Health. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- Someone who wants a bundled support model and will confirm the prescribed formulation in writing.
- Wrong for
- Someone assuming every route in a broad menu has the evidence or approval of a branded injection.
The evidence behind what KIN Health prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How KIN Health compares
| Seller | Who it suits | Go |
|---|---|---|
| SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | See SkinnyRx → |
| ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | See ShedRx → |
| RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | See RxSpan MD → |
More GLP-1 telehealth sellers reviews: Mint MedMint Medical ClinicMochi HealthMojoonMondaeMultiMedRx
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Are the formulations proven by the cited brand trials?
- KIN itself says its compounded formulations have not been independently studied. Brand trials should not be treated as direct evidence for every listed route.
- Is provider support a separate membership?
- The homepage describes provider care and messaging as included without an additional membership fee.
Sources for this review
Provider information checked . Terms can change.